Findings

What do systematic reviews say?

86 questions · 86 findings · 8 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 29 · 33.7%GRADE not reported 17 · 19.8%Very low 13 · 15.1%Low 16 · 18.6%Moderate 11 · 12.8%High 0 · 0%

Colchicine plus standard care vs placebo or usual care

Adverse events ( · individuals with moderate or severe COVID‐19

1 finding from 1 review

Colchicine for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Very low

Colchicine plus standard care vs placebo or usual care

Serious adverse events ( · individuals with moderate or severe COVID‐19

1 finding from 1 review

Colchicine for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Very low

Colchicine single dose vs divided dose

Number of participants experiencing an attacka · children with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine single dose vs divided dose

Duration of attacksa · children with familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Moderate

Colchicine single dose vs divided dose

Time between attacks · children with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine single dose vs divided dose

Prevention of AA amyloidosis · children with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine single dose vs divided dose

Adverse drug reactions · children with familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Moderate

Colchicine single dose vs divided dose

Acute‐phase response · children with familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Colchicine (0.5 mg three times per day) vs Clofazimine (100 mg daily for 30 days, then 100 mg every other day)

Complete remission, pain intensity, patient and physician evaluation · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
6 months
One trial at high risk of bias (de Abreu 2009) compared clofazimine (n=23) with colchicine (n=23). The number with no further aphthous episodes at 6 months was significantly greater in the clofazimine group than the…
1 study · 46 participants
GRADE not reported

Colchicine (0.5 mg three times per day) vs Clofazimine (100 mg daily for 30 days, then 100 mg every other day)

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
6 months
Clofazimine was associated with an increase in cutaneous adverse effects (Fisher's exact test P=0.015), easily controlled; there was a greater percentage of treatment interruptions in the colchicine group due to…
1 study · 46 participants
GRADE not reported

Colchicine (0.5 mg three times per day) vs placebo

Complete remission (no further aphthous episodes to 6 months) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
6 months
The trial by de Abreu 2009 (high risk of bias) also assessed colchicine (n=23) versus placebo (n=20). The number with no further aphthous episodes at 6 months was not significantly different from placebo (Fisher's…
1 study · 43 participants
GRADE not reported

Colchicine (0.5 mg three times per day) vs placebo

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
6 months
There was a greater percentage of treatment interruptions in the colchicine group due to gastrointestinal adverse effects (Fisher's exact test P=0.009). The review noted potential evidence of harm at a dose of 1.5 mg…
1 study · 43 participants
GRADE not reported

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Pain at completion of treatment · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Colchicine (0.5 mg per day for 3 months) showed no clear difference in pain at completion of treatment compared with prednisolone (5 mg per day for 3 months); GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
3 months
MD -0.16 [-1.18, 0.86]
1 study · 34 participants
GRADE not reported

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Number of (minor aphthous) oral ulcers · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Colchicine (0.5 mg per day for 3 months) showed no clear difference in number of aphthous ulcers at completion compared with prednisolone (5 mg per day for 3 months); GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
3 months
MD -0.13 [-0.50, 0.24]
1 study · 34 participants
GRADE not reported

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
3 months
Colchicine was associated with statistically significantly more adverse effects than prednisolone (nine participants reporting adverse effects on colchicine versus two on prednisolone).
1 study · 34 participants
GRADE not reported

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Recurrence · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Colchicine (0.5 mg per day for 3 months) showed no clear difference in recurrence during treatment period compared with prednisolone (5 mg per day for 3 months); GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
3 months
RR 1.30 [0.98, 1.71]
1 study · 34 participants
GRADE not reported

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Mortality at maximal · people with primary biliary cholangitis

It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
OR 1.84 [0.38, 8.91]
2 studies · 158 participants
Very low

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (proportion) · people with primary biliary cholangitis

It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes serious adverse events (proportion) compared with UDCA (very low certainty).

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
OR 3.08 [0.12, 78.14]
1 study · 74 participants
Very low

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Health‐related quality of life · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found